Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis

Most non-small cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) mutations respond to tyrosine kinase inhibitor (TKI) therapy. However, about 30% exhibit primary resistance to EGFR TKI therapy. Here we report that Met protein expression and phosphorylatio...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Benedettini, Elisa, Sholl, Lynette M., Peyton, Michael, Reilly, John, Ware, Christopher, Davis, Lenora, Vena, Natalie, Bailey, Dyane, Yeap, Beow Y., Fiorentino, Michelangelo, Ligon, Azra H., Pan, Bo-Sheng, Richon, Victoria, Minna, John D., Gazdar, Adi F., Draetta, Giulio, Bosari, Silvano, Chirieac, Lucian R., Lutterbach, Bart, Loda, Massimo
Format: Artigo
Jezik:Inglês
Izdano: American Society for Investigative Pathology 2010
Teme:
Regular Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2893683/
https://ncbi.nlm.nih.gov/pubmed/20489150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2353/ajpath.2010.090863
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki